Compare ANGI & AVXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ANGI | AVXL |
|---|---|---|
| Founded | 1995 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 180.9M | 237.2M |
| IPO Year | 2017 | 2013 |
| Metric | ANGI | AVXL |
|---|---|---|
| Price | $4.86 | $3.25 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 3 |
| Target Price | $17.00 | ★ $22.00 |
| AVG Volume (30 Days) | 841.9K | ★ 902.2K |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1242.86 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $736,386,000.00 | N/A |
| Revenue This Year | $3.25 | N/A |
| Revenue Next Year | $3.76 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 47.60 | N/A |
| 52 Week Low | $4.26 | $2.26 |
| 52 Week High | $18.70 | $10.40 |
| Indicator | ANGI | AVXL |
|---|---|---|
| Relative Strength Index (RSI) | 45.12 | 58.78 |
| Support Level | $4.57 | $2.93 |
| Resistance Level | $6.52 | $3.53 |
| Average True Range (ATR) | 0.34 | 0.17 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 28.35 | 54.33 |
Angi Inc connects quality home service professionals with consumers across different categories, from repairing and remodeling to cleaning and landscaping. It operates through brands like Angi, HomeAdvisor, and Handy. The company has three operating segments, namely, Ads and Leads, Services, and International (Europe and Canada). A majority of its revenue is generated from the Ads and Leads segment, which provides professionals the capability to engage with potential customers, including quoting and invoicing services, and provides consumers with tools and resources to help them find professionals nationwide for home repair, maintenance, and improvement projects. Geographically, the company derives its key revenue from the United States and also has a presence in other countries.
Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.